Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
449 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07441486 | A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT06452602 | Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC. | recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Feb 27, 2026 |
| clinicaltrials |
| NCT07432568 | A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT05263947 | Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation | completed | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07409298 | Impact of an Artificial Intelligence-Based Management Model on Psychological and Behavioral Outcomes in Breast Cancer Patients Undergoing Home CDK4/6 Inhibitor Therapy | enrolling by invitation | N/A | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410234 | Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT05787522 | Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk | completed | — | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407439 | Real-world Studies of CDK4/6 Inhibitors | recruiting | — | 245 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07407985 | A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors(GK01IIT-TZ03) | active not recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06009627 | Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients | completed | Phase 2 / Phase 3 | 119 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05644379 | A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma | active not recruiting | Phase 1 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05685550 | Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study | active not recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07388095 | Adebrelimab Neoadjuvant Treatment for Resectable ESCC | not yet recruiting | N/A | 22 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 4, 2026 | clinicaltrials |
| NCT07374068 | Prognostic Model of Elderly Hodgkin Lymphoma in China | active not recruiting | — | 400 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06951997 | QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status | recruiting | Phase 3 | 394 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07351903 | A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors(GUARDIAN-02) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 216 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy | recruiting | Phase 2 | 41 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07330050 | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07324876 | A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC) | not yet recruiting | — | 860 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07307287 | SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07304739 | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07302841 | Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer | not yet recruiting | Phase 4 | 28 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT07298538 | Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer | active not recruiting | — | 800 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06498154 | Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy | recruiting | Phase 2 | 200 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy | not yet recruiting | Phase 2 | 36 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07272291 | A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT07263360 | Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer | not yet recruiting | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07246317 | Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer | not yet recruiting | Phase 2 | 188 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07254416 | A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients | not yet recruiting | Phase 4 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07244874 | Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC | not yet recruiting | Phase 2 | 41 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07244926 | Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 31 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT06023966 | A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery | completed | — | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06352008 | To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer | recruiting | Phase 2 | 64 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07172412 | Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 165 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07183150 | The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer(Range of 4sb) | recruiting | — | 400 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06339307 | A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients | completed | — | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07179445 | Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy | not yet recruiting | — | 300 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07167459 | Personalized SBRT in Early-Stage Peripheral NSCLC | enrolling by invitation | Phase 2 | 251 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT07162519 | Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients | not yet recruiting | N/A | 68 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Sep 9, 2025 | clinicaltrials |
| NCT07157306 | Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07153965 | Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07099274 | Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07141186 | QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 59 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 24, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials